Last €0.63 EUR
Change Today +0.009 / 1.45%
Volume 0.0
HG6 On Other Exchanges
Symbol
Exchange
Berlin
OTC US
As of 2:15 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

mayne pharma group ltd (HG6) Snapshot

Open
€0.63
Previous Close
€0.62
Day High
€0.63
Day Low
€0.63
52 Week High
03/24/14 - €0.67
52 Week Low
12/15/14 - €0.37
Market Cap
491.7M
Average Volume 10 Days
230.0
EPS TTM
--
Shares Outstanding
783.0M
EX-Date
03/3/11
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MAYNE PHARMA GROUP LTD (HG6)

Related News

No related news articles were found.

mayne pharma group ltd (HG6) Related Businessweek News

No Related Businessweek News Found

mayne pharma group ltd (HG6) Details

Mayne Pharma Group Limited, a specialty pharmaceutical company, develops, manufactures, and distributes branded and generic products. The company’s products include Doryx capsules and tablets for the treatment of severe acne and as an anti-malarial; Eryc capsules for the treatment of various bacterial infections; ESGIC and ZEBUTAL capsules for the treatment of tension headaches; Kapanol and Kadian capsules for the management of moderate to severe chronic pain; LORCET tablets; LOZANOC antifungal agent; and Urocarb tablets. Its OTC/pharmacy products comprise Astrix tablets for cardiovascular and cerebrovascular diseases; Licener, a treatment for children suffering from head lice; Magnoplasm paste that exerts osmotic action on living cells; and Percutane pain relief and sports cream. The company also offers Doxycycline capsules to treat certain types of infections; Erythromycin capsules for bacterial infections; and contract development and manufacturing services. In addition, the company provides Amiodarone HCl tablets for life-threatening recurrent ventricular arrhythmias; Bromfenac anti-inflammatory drug for the treatment of postoperative inflammation and reduction of ocular pain; Butalbital/APAP/caffeine capsules; Hydrocodone/APAP tablets for the relief of moderate to severe pain; Methamphetamine tablets for attention deficit disorder; Liothyronine sodium tablets for the treatment of hypothyroidism and come; Nystatin topical powder for the treatment of fungal infections; Oxycodone capsules for the management of moderate to severe acute and chronic pain; and Oxycodone/APAP tablets for the relief of moderate to moderately severe pain. Mayne Pharma Group sells its products directly or through distribution partners primarily in the United States, Australia, and Korea. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited is based in Melbourne, Australia.

500 Employees
Last Reported Date: 08/26/14

mayne pharma group ltd (HG6) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$601.3K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$403.0K
President of Mayne Pharma USA
Total Annual Compensation: A$369.4K
Compensation as of Fiscal Year 2014.

mayne pharma group ltd (HG6) Key Developments

Actavis plc to Divest Doryx to Mayne Pharma

Actavis plc announced that it has entered into an agreement with Mayne Pharma, under which it will divest the U.S. rights to the Doryx brand acne treatment and related assets to Mayne for approximately $50 million. The transaction is expected to close prior to the end of February. Under the terms of the agreement, Actavis will continue to package, distribute and actively promote the product for a transition period until May 2 following the close of the transaction.

Mayne Pharma Group Limited Announces Revenue Results for the Year to Date Ended October, 2014

Mayne Pharma Group Limited announced revenue results for the year to date ended October 2014. For the period, the company reported revenue of $38.1 million, 14% weaker than $44.6 million at this time last year.

Mayne Pharma Appoints Andrew O. Herdman as Vice President of Human Resources for its Operations in the United States

Mayne Pharma has appointed Andrew O. Herdman, Ph.D., as vice president of human resources for its operations in the United States. Herdman – who most recently served as associate professor of management at the East Carolina University College of Business – is responsible for developing robust and scalable human resource management processes for the growing pharmaceutical corporation. Herdman joins Mayne Pharma from the East Carolina University College of Business, where he served as an associate professor of management since 2007.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HG6:GR €0.63 EUR +0.009

HG6 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HG6.
View Industry Companies
 

Industry Analysis

HG6

Industry Average

Valuation HG6 Industry Range
Price/Earnings 31.6x
Price/Sales 3.9x
Price/Book 2.9x
Price/Cash Flow 31.7x
TEV/Sales 4.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MAYNE PHARMA GROUP LTD, please visit www.maynepharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.